NeOnc Technologies Holdings (NASDAQ:NTHI) recently broke above the $3 resistance level on strong volume, signaling a potential technical reversal from lows near $2.50. This breakout coincides with growing clinical milestones, including investigational brain tumor therapies and a new memorandum of understanding with Abu Dhabi's Department of Health to support oncology research and clinical training. The company also reported positive early clinical observations in critically ill children receiving its investigational treatment. With an FDA meeting scheduled for November 17 and upcoming media exposure on Fox Business, NeOnc's stock movement reflects both technical strength and fundamental progress. Analysts have set price targets averaging $17, highlighting optimism around the company's growth potential.
NeOnc Technologies Holdings' recent stock activity is presented here with Pluang's Health-sector market data as of Oct 24, 2026 00:21 WIB. Among 150 priced Health-sector US stocks tradable on Pluang, 47 rose and 103 fell today. Notable movers include CTXR at USD 0.40 with a 1-day change of +7.87% and Pluang order activity of 0% Sell / 100% Buy, OSCR at USD 31.81 down 4.53% with 4% Sell / 96% Buy, and AMPH at USD 24.90 down 4.38%. The most notable figure is CTXR's full buy-side order activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
